News | Implantable Cardiac Monitor (ICM) | July 01, 2019

Biotronik Launches Biomonitor III Injectable Cardiac Monitor in Europe

Next-generation ICM makes injection, monitoring and diagnosis of arrhythmias easy and efficient

Biotronik Launches Biomonitor III Injectable Cardiac Monitor in the CE Region

July 1, 2019 – Biotronik announced the European market release of its new injectable cardiac monitor (ICM), Biomonitor III, following CE mark approval. The novel device is designed to help patients with irregular heart rhythms by documenting suspected arrhythmia or unexplained syncope with increased clarity.

As the most common type of arrhythmia, 33.5 million patients worldwide suffer from atrial fibrillation (AF).1 It is associated with a five-fold increase in risk of stroke, a three-fold increase in incidence of congestive heart failure and higher mortality.2 Aiming to improve the accuracy of arrhythmia detection and diagnosis, Biotronik’s new ICM offers increased signal quality.3

“What I like about Biomonitor III is the ease of use and the high signal fidelity,” said Associate Prof. Paul Gould, cardiologist and electrophysiologist at St Andrew’s War Memorial Hospital, Brisbane, Australia. “This coupled with the automatic Home Monitoring provides an excellent resource to establish a rhythm symptom correlation or to detect occult arrhythmias in my patients." 

Biomonitor III’s BIOvector technology is designed to deliver high-definition signals. As a result, the high signal amplitudes and visibility of the p-waves3 make it easier for the physician to confidently evaluate arrhythmias. 

Biotronik’s next-generation ICM is 60 percent smaller than its predecessor, BioMonitor 2, and comes ready to inject, with the device pre-assembled in a one-piece injection tool. To optimize patient comfort, Biomonitor III offers a very small size and flexible sensing antenna. The device is injected under the skin with a very small incision, facilitating in-office treatments. 

The device works with Biotronik’s fully automated, ‘plug in and go’ Home Monitoring. Due to automatic pairing, initialization and data transmission, no active patient involvement is required. The new product also features Intelligent Memory Management, which prevents the overwriting of clinically relevant episodes. Thus, no relevant information is missed.

For more information: www.biotronik.com

 

References

1. Chugh S.S. et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 study. Circulation, 129 (2014):837-847.

2. Camm A.J. et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012;33(21):2719–2747.

3. BIO|CONCEPT.BIOMONITOR III Study. Data on file.

Related Content

New Technology Improves Atrial Fibrillation Detection After Stroke
News | Atrial Fibrillation | July 19, 2019
A new method of evaluating irregular heartbeats outperformed the approach that’s currently used widely in stroke units...
An screen shot of the Abbott Focal Impulse and Rotor Modulated (FIRM)-guided ablation system used to guide AF ablation procedures.

An screen shot of the Abbott Focal Impulse and Rotor Modulated (FIRM)-guided ablation system used to guide AF ablation procedures. 

News | Atrial Fibrillation | May 14, 2019 | Dave Fornell, Editor
May 14, 2019 – The first prospective, multicenter, randomized, controlled trial to compare conventional pulmonary vei
The Parasym Salustim device ear clip stimulates the vagus nerve, which was found to reduced AF burden compared with a sham procedure in the TREAT AF trial.

The Parasym Salustim device ear clip stimulates the vagus nerve, which was found to reduced AF burden compared with a sham procedure in the TREAT AF trial. 

News | Atrial Fibrillation | May 13, 2019
May 13, 2019 — A randomized clinical trial effectively used nerve stimulation through an ear clip to reduce...
More than 60,000 from the general population in Belgium were screened for AFib using only a smartphone app in the DIGITAL-AF II study. The study used the FibriCheck app found 791 participants has measurements indicative for AF.

More than 60,000 from the general population in Belgium were screened for AFib using only a smartphone app in the DIGITAL-AF II study. The study used the FibriCheck app found 791 participants has measurements indicative for AF.

News | Atrial Fibrillation | May 13, 2019
May 13, 2019 — A digital screening for...
Rivaroxaban is among four new oral anticoagulants (NOAC) now recommended by atrial fibrillation guidelines over the old standard of warfarin.

Rivaroxaban is among four new oral anticoagulants (NOAC) now recommended by atrial fibrillation guidelines over the old standard of warfarin.

 

Feature | Atrial Fibrillation | January 30, 2019
January 30, 2019 — Updated atrial fibrillation (AFib) treatment guidelines released this week now recommend new oral
Aurigen Medical Atrial Fibrillation Device Wins ICI Innovation Award
News | Atrial Fibrillation | December 18, 2018
Irish medical device company AuriGen Medical won the prestigious Global Innovation Award at the International...

An example of the new generation of cardiac monitoring device that is replacing Holter monitoring is the Cardea Solo wearable sensor. The FDA-cleared device automatically analyzes data when the device is turned back into the physician's office and automatically produces a draft summary report. This technology can simplify the workflow by eliminating the need for third-party involvement.

Feature | Atrial Fibrillation | September 13, 2018
Rapid advances in technology to monitor atrial fibrillation (AF or Afib) are enabling clinicians to access real-time
Overlay Init